Physician CME

A growing body of evidence has demonstrated the correlation between fluctuations in retinal fluid and worse anatomical and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) treated with intravitreal anti-vascular endothelial growth factor therapies. Appropriate selection of treatment and dosing regimens that prioritize stability of retinal anatomy while minimizing fluctuations in central retina thickness are essential for achieving optimal outcomes.

Therapies that offer longer duration of action have the potential to stabilize the retinal anatomy and minimize fluctuations in retinal fluid. In this CE activity, experts in the field will review how fluctuations in retinal fluid may negatively impact anatomical and functional outcomes in patients with nAMD and DME, as well as evaluate the latest clinical and real-world evidence for therapies that can improve retina fluid control and lessen fluctuations in central subretinal thickness. The presentation of challenging, real-world cases also allows for the application of this valuable content into clinical practice.